PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]
PLX
Protalix Biotherapeutics – A Compelling Buy Due To Validation Of Oral Protein Delivery Technology
moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]
7:33 am Protalix BioTherapeutics oral GCD data to be presented at WORLD Symposium 2014; with a daily oral administration of Oral GCD, co expects to achieve a steady state level of active GCD enzyme in the blood circulation of patients simil
moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]
Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014
[GlobeNewswire] – CARMIEL, Israel — Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) announced today that phase I clinical trial data for oral GCD (PRX-112) for the treatment of Gaucher disease will be presented by Professor … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]
Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease
[at noodls] – CARMIEL, Israel, April 2, 2013 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been treated in the Company’s phase I clinical trial … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]
UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease
[at noodls] – NEW YORK and CARMIEL, Israel, March 18, 2013 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that the Brazilian National Health Surveillance … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]
Protalix BioTherapeutics Reviewing Partnering and Other Alternatives
[at noodls] – CARMIEL, Israel, Feb. 5, 2013 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX) (TASE:PLX), confirms, in response to inquiries received this morning and a report appearing in the Israeli … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]
Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium
[at noodls] – CARMIEL, Israel, Jan. 31, 2013 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that new clinical data on taliglucerase alfa will be presented at the 9th Annual … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]
Protalix BioTherapeutics Announces First Patient Treated in Phase I/II Study of Fabry Patients With PRX-102
[at noodls] – CARMIEL, Israel, Dec. 10, 2012 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the first patient has been treated in the Company’s phase I/II clinical … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]
